Patents Assigned to United States of America, as represented by the Secretary, Department of Health and Human Services
-
Patent number: 12270738Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.Type: GrantFiled: April 8, 2022Date of Patent: April 8, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
-
Patent number: 12270814Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.Type: GrantFiled: October 6, 2023Date of Patent: April 8, 2025Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Patent number: 12269155Abstract: The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.Type: GrantFiled: May 4, 2021Date of Patent: April 8, 2025Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Thomas Jefferson University, University of Maryland, BaltimoreInventors: Reed F. Johnson, Matthias Schnell, Lisa E. Hensley, Christoph Wirblich, Christopher M. Coleman, Matthew S. Frieman
-
Patent number: 12269872Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: GrantFiled: May 4, 2020Date of Patent: April 8, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
-
Patent number: 12268700Abstract: Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.Type: GrantFiled: March 25, 2019Date of Patent: April 8, 2025Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of ConnecticutInventors: Lise H. Pasquet, Jay A. Berzofsky, Amy R. Howell, Masaki Terabe, Kaddy Camara, Stewart K. Richardson
-
Patent number: 12268737Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: April 26, 2024Date of Patent: April 8, 2025Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Publication number: 20250095390Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.Type: ApplicationFiled: May 13, 2024Publication date: March 20, 2025Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kapil Bharti, Nathan A. Hotaling, Nicholas J. Schaub, Carl G. Simon
-
Patent number: 12251432Abstract: Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.Type: GrantFiled: October 21, 2020Date of Patent: March 18, 2025Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Sara Lustigman, Thomas B. Nutman, Sasisekhar Bennuru
-
Patent number: 12247250Abstract: The present invention relates to the rapid and electricity-free, point-of-care, multiplexed detection and quantification of at least one or more nucleic acid sequences from nucleic acids corresponding to a plurality of pathogens or biomarkers using a micropatterned lateral flow device. Rapid and molecular-level sensitive differential diagnosis of a disease condition may be enabled without the need for a delayed laboratory test so that timely treatment can be administered.Type: GrantFiled: July 28, 2020Date of Patent: March 11, 2025Assignees: GODX, INC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Chang Hee Kim, Wendy A. Henderson, Sarah K. Abey, Nicolaas H. Fourie, Eric G. Ferguson
-
Patent number: 12239654Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.Type: GrantFiled: April 21, 2017Date of Patent: March 4, 2025Assignees: Astrocyte Pharmaceuticals, Inc., Board of Regents, The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: William S. Korinek, James D. Lechleiter, Theodore E. Liston, Kenneth A. Jacobson
-
Patent number: 12233124Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.Type: GrantFiled: September 6, 2023Date of Patent: February 25, 2025Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
-
Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
Patent number: 12233051Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.Type: GrantFiled: July 14, 2023Date of Patent: February 25, 2025Assignees: VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers -
Patent number: 12227554Abstract: Disclosed are methods of selectively expanding a number of T cells. The methods may comprise: modifying human T cells to express a TCR, wherein the TCR comprises a murine constant region; producing a population of cells comprising a number of human T cells expressing the TCR and a number of human T cells not expressing the TCR; and culturing the population of cells in the presence of (i) irradiated feeder cells, (ii) one or more cytokines, and (iii) an antibody, or an antigen-binding portion thereof, wherein the antibody has antigenic specificity for the murine constant region of the TCR, so as to selectively expand the number of T cells expressing the TCR over the number of T cells not expressing the TCR. Also disclosed are related populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: GrantFiled: September 24, 2018Date of Patent: February 18, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Drew C. Deniger, Steven A. Feldman, Steven A. Rosenberg
-
Publication number: 20250049952Abstract: Polynucleotide expression cassettes comprising synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) are described herein. Related recombinant expression vectors, recombinant adeno-associated viruses (rAAVs), and compositions are also described. Also described are methods of treating a disease or condition mediated by propionyl-CoA carboxylase, comprising administering to a subject in need thereof a therapeutic amount of any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions.Type: ApplicationFiled: December 29, 2022Publication date: February 13, 2025Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Charles P. Venditti, Randy J. Chandler
-
Patent number: 12221627Abstract: Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.Type: GrantFiled: December 3, 2018Date of Patent: February 11, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gal Cafri, Steven A. Rosenberg
-
Patent number: 12215349Abstract: Disclosed are methods of preparing thymic emigrant cells in vitro, isolated or purified thymic emigrant cells prepared by the methods, and pharmaceutical compositions comprising the same. Further disclosed are methods of treating or preventing a condition in a mammal comprising administering the thymic emigrant cells or pharmaceutical compositions comprising the same to the mammal.Type: GrantFiled: December 13, 2017Date of Patent: February 4, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Raul E. Vizcardo, Nicholas D. Klemen, Nicholas P. Restifo
-
Patent number: 12215164Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: GrantFiled: September 20, 2023Date of Patent: February 4, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
-
Publication number: 20250034244Abstract: An embodiment of the invention provides chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.Type: ApplicationFiled: April 24, 2024Publication date: January 30, 2025Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Haiying Qin, Crystal L. Mackall, Terry J. Fry
-
Patent number: 12208093Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.Type: GrantFiled: February 11, 2022Date of Patent: January 28, 2025Assignees: The Johns Hopkins University, THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human ServicesInventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
-
Patent number: 12210017Abstract: Methods of identifying a subject with a Filovirus infection are provided herein. In some embodiments, the method comprises contacting a biological sample containing antibodies from the subject with one or more peptides comprising amino acid sequences of selected Filovirus epitopes, detecting the presence or absence of an immune complex of antibodies from the biological sample with the one or more peptides; and wherein the presence of the immune complex identifies the subject as having Filovirus infection and the absence of the immune complex identifies the subject as not having Filovirus infection. Further provided are isolated peptides for use in such methods, as well as a solid support linked to one or more of the disclosed peptides.Type: GrantFiled: January 8, 2021Date of Patent: January 28, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana